Authors: Ioannis Passarisa, Stéphanie Depickèreb, Chloé Abelsc, Jessica Vandenhautec, Raymond Vanhoofa, Pieter-Jan Ceyssensa a Bacterial Diseases Unit, Sciensano, Brussels, Belgium b Platform for Interventional Studies, Sciensano, Brussels, Belgium c MSD Belgium, Brussels, Belgium… Read More »Reshaping Adult Pneumococcal Disease Through Paediatric Vaccination
Growing scientific evidence continues to highlight the important role of the Epstein–Barr virus (EBV) in the development of multiple sclerosis (MS). A recent article published… Read More »Epstein–Barr Virus and Multiple Sclerosis: New Research Strengthens the Link
Published on: April 20, 2026 – Keith Chappell, Scientific Advisor at Sanofi Most people don’t think about how a vaccine is designed. They think about… Read More »Shape Matters: Inside Molecular Clamp Vaccines
Hasselt, Belgium & Leiden, The Netherlands – April 7th, 2026 We are proud to highlight a new strategic collaboration between our member, simAbs, and Ardent… Read More »simAbs and Ardent Biopharma Announce Strategic Partnership to Advance Next-Generation Biosimilar Manufacturing
SwiftPharma and Benno Therapeutics are taking a next step in their collaboration by establishing a dedicated R&D presence in Leuven. While SwiftPharma remains headquartered at… Read More »SwiftPharma and Benno Therapeutics expand R&D footprint with new collaborative site in Leuven
Authors: Lara Kelchtermans, Katrien Geerts, Cuong Thi Pham, Vanshika Malviya, Winston Chiu, Carolien De Keyzer, Elias Broeckhoven, Johan Neyts, Susan Schlenner, Yeranddy A. Alpizar & Kai Dallmeier Journal: Nature immunologyPublished: 25 March 2026DOI: https://doi.org/10.1038/s41590-026-02478-7 Abstract Recurring outbreaks… Read More »CD4+ T cell-mediated immunity protects from VSV-SUD lethal challenge in a mouse model of Sudan virus infection
Today, Sagitta Biotech announced positive preclinical results for its Flu vaccine candidate, demonstrating robust immunogenicity and efficacy in mice. These findings represent a significant development… Read More »Sagitta Biotech Announces Positive Preclinical Results, Marking a Key Milestone in Platform development and Pipeline Advancement
Nantes, France and Geneva, Switzerland, March 9, 2026 – Naobios, a Contract Development and Manufacturing Organization (CDMO) providing bioprocess development and GMP production of clinical batches… Read More »Naobios and SGS partner to manufacture Respiratory Syncytial Virus (RSV) challenge agent
SimAbs has successfully raised €5 million in a Series A funding round, marking an important milestone in the company’s mission to transform the way antibodies… Read More »SimAbs raises €5M Series A to scale continuous antibody manufacturing
About this white paper This white paper is an evidence-based call to action for Belgian policymakers on the implementation of tools required to eliminate HPV-related… Read More »Advancing public health: a roadmap to the implementation of tools required to eliminate HPV-related cancers and diseases in Belgium by 2030
